rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
|
20574956 |
2010 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence shows that exon 19 deletions (19del) and exon 21 Leu858Arg point mutation (L858R) of EGFR are different in response to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in advanced lung cancers.
|
29026990 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aim to develop a digital PCR-based method for the quantitative detection of the two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon 19 and L858R at exon 21) in the plasma and tumor tissues of patients suffering from non-small cell lung cancers.
|
19276259 |
2009 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice.
|
25320360 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The loop-hybrid mobility shift assay (LH-MSA) was previously developed for the rapid detection of the EGFR mutation L858R for predicting clinical responses to gefitinib in lung cancer.
|
21741959 |
2011 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We identified all patients with metastatic <i>EGFR</i> exon19del or L858R-mutant lung cancers treated with first/second-generation EGFR tyrosine kinase inhibitors (TKIs) with pretreatment next-generation sequencing data (MSK-IMPACT assay).
|
30045933 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation.
|
23937717 |
2013 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the LightCycler PCR assay, the EGFR L858R mutation status might correlate with gender, pathologic subtypes, and gefitinib sensitivity of lung cancers.
|
15837743 |
2005 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To further access a physiological role of MALT1-dependent NF-κB activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression.
|
25982276 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
|
27643705 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic analysis suggested that the specific EGFR mutation L858R in exon 21 might be the main factor contributing to lung carcinogenesis in multiple lung cancers.
|
22733594 |
2012 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity.
|
24429876 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion).
|
28774798 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The EGFR mutation status, especially L858R mutation might be correlated with the clinico-pathological features related to good response to gefitinib, such as gender, smoking history, and pathological subtypes of Japanese lung cancers.
|
16890322 |
2006 |